FOXO TECHNOLOGIES INC. ANNOUNCES THAT STOCKHOLDERS EQUITY IS GREATER THAN $4M, WHICH IS REQUIRED TO MEET THE CONTINUED LISTING REQUIREMENTS OF THE NYSE AMERICAN EXCHANGE
FOXO TECHNOLOGIES INC. ANNOUNCES THAT STOCKHOLDERS EQUITY IS GREATER THAN $4M, WHICH IS REQUIRED TO MEET THE CONTINUED LISTING REQUIREMENTS OF THE NYSE AMERICAN EXCHANGE
MINNEAPOLIS, MN, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company" or "FOXO") announces that recent transactions have led to the Company having stockholders equity greater than $4M and, as a result, it has regained compliance with NYSE American continued listing requirements for stockholders equity.
明尼阿波利斯,MN,2024年12月16日(环球新闻网络)-- FOXO科技公司(纽交所美国:FOXO)(以下简称“公司”或“FOXO”)宣布,最近的交易使得公司的股东权益超过400万美元,因此,它已重新符合纽交所美国对股东权益的持续上市要求。
As was disclosed in the Company's Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the "SEC") on November 19, 2024, the Company had a stockholders' deficit of approximately $17.5 million in its unaudited financial statements as of September 30, 2024. Since then, the Company has been working to secure agreements from certain creditors, debt holders, and investors to exchange their debt to equity in the form of Preferred Stock which would be treated as equity.
正如公司于2024年11月19日提交给美国证券交易委员会(“SEC”)的10-Q季度报告中披露的,截止到2024年9月30日,公司在未经审计的基本报表中显示出约1750万的股东赤字。自那以来,公司一直在努力与某些债权人、债务持有人和投资者达成一致,以将其债务以优先股的形式转换为股权。
The Company was successful in securing:
公司成功达成了:
- Rennova Health, Inc.'s exchange of $21 million of the Company's Senior Secured Note issued by Rennova Community Health, Inc. (the Company's wholly owned subsidiary) into 21,000 shares of the Company's Series A Cumulative Convertible Redeemable Preferred Stock ("Series A Preferred Stock")
- An institutional investor's additional funding of $1.0 million and exchange of approximately $2.2 million of Senior Notes (including the newly issued approximately $1.0 million) into 2,464 shares of the Company's Series A Preferred Stock
- Settlement of certain liabilities owed to KR8 AI, Inc., and the termination of a license agreement in exchange for 3,000 shares of the Company's newly designated Series D Cumulative Convertible Redeemable Preferred Stock
- Additionally, the Company had approximately $1.0 million of other liabilities and notes converted to approximately 2 million shares of Class A Common Stock since October 1, 2024
- Rennova Health, Inc. 将2100万公司的高级担保票据转换为21,000股公司的A系列可累积可转换可赎回优先股("A系列优先股")
- 一名机构投资者提供的额外融资100万,并将约220万的高级票据(包括新发行的约100万)转换为2,464股公司的A系列优先股
- 结清对KR8人工智能公司的某些负债,以及在交换3000股公司新指定的D系列可累积可转换可赎回优先股的情况下终止一项许可协议
- 此外,自2024年10月1日以来,公司有约100万的其他负债和票据转换为约200万股A类普通股
"I am delighted we can inform our shareholders that stockholder's equity is now greater than $4 million," said Seamus Lagan, the Company's Chief Executive Officer. "We believe this eliminates the risk of delisting from NYSE American for a stockholders equity deficiency that has hung over the Company for the past 18 months. We are committed to continued growth and improvements for the benefit of our shareholders in the coming years," continued Mr. Lagan.
“我很高兴能通知我们的股东,股东权益现在超过400万,”公司首席执行官Seamus Lagan说。“我们相信这消除了由于股东权益不足而导致的从纽约证券交易所美国退市的风险,这种风险困扰了公司长达18个月。我们致力于在未来几年继续为我们的股东带来增长和改善,”Lagan先生继续说道。
The Company filed a Current Report on Form 8-K with the SEC on December 10, 2024, which provides additional details on the above transactions and related Company actions and activities. If at any time in the future the Company falls out of compliance with the stockholders equity requirements to meet NYSE American continued listing rules, the Company would be subject to immediate reevaluation by NYSE American.
公司于2024年12月10日向证监会提交了8-K表格的当前报告,提供了有关上述交易及相关公司行动和活动的更多细节。如果未来公司不再符合满足纽交所美国挂牌续存规则的股东权益要求,公司将面临纽交所美国的即时重新评估。
About FOXO Technologies Inc. ("FOXO")
关于FOXO科技公司("FOXO")
FOXO owns and operates three subsidiaries.
FOXO拥有并运营三家子公司。
Foxo Labs, Inc. is a biotechnology company dedicated to improving human health and life span through the development of cutting-edge technology and product solutions for various industries.
Foxo Labs, Inc.是一家生物技术公司,致力于通过开发前沿科技和产品解决方案来改善人类健康和寿命,面向各个行业。
Myrtle Recovery Centers, Inc., a 30-bed behavioral health facility in East Tennessee. Myrtle provides inpatient services for detox and residential treatment and outpatient services.
Myrtle Recovery Centers, Inc.是一家位于东田纳西州的30床位的行为健康设施。Myrtle提供戒毒和住院治疗的住院服务以及门诊服务。
Rennova Community Health, Inc., owns and operates Scott County Community Hospital, Inc. (d/b/a Big South Fork Medical), a critical access designated (CAH) hospital in East Tennessee.
Rennova社区医疗公司拥有并运营斯科特县社区医院(商业名称:大南叉医疗),这是一家位于东田纳西州的关键接入指定医院。
For more information about FOXO, visit .
有关FOXO的更多信息,请访问 .
Forward-Looking Statements [BH should review and clean-up for next time]
前瞻性声明 [BH 应该为下次审核并清理该内容]
This press release contains certain forward-looking statements for purposes of the "safe harbor" provisions under the United States Private Securities Litigation Reform Act of 1995. Any statements other than statements of historical fact contained herein, including statements about trading of the Warrants in the over-the-counter market, the continued listing of the Company's Class A common stock on NYSE American, and other statements identified by words such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "believe," "intend," "plan," "projection," "outlook" or words of similar meaning, but the absence of these words does not mean that a statement is not forward-looking. Any such forward-looking statements are based upon the current beliefs and expectations of the Company's management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond the Company's control. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the possibility that the Plan will not be accepted by NYSE American, the Company will be unable to satisfy other continued listing requirements of NYSE American for its Class A common stock to maintain the listing of the Class A common stock on NYSE American; the risk of changes in the competitive and highly regulated industries in which FOXO operates; variations in operating performance across competitors or changes in laws and regulations affecting FOXO's business; the ability to implement FOXO's business plans, forecasts, and other expectations; the ability to obtain financing; the risk that FOXO has a history of losses and may not achieve or maintain profitability in the future; potential inability of FOXO to establish or maintain relationships required to advance its goals or to achieve its commercialization and development plans; the enforceability of FOXO's intellectual property, including its patents and the potential infringement on the intellectual property rights of others; and the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry or in the markets or industries in which FOXO operates. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties discussed in FOXO's most recent reports on Forms 10-K and 10-Q, particularly the "Risk Factors" sections of those reports, and in other documents FOXO has filed, or will file, with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
本新闻稿包含某些前瞻性声明,以符合1995年《美国私人证券诉讼改革法》的“安全港”条款。除历史事实外,本文所包含的任何声明,包括关于 Warrants 在场外市场交易的声明、公司A类普通股在纽约证券交易所(NYSE American)持续上市的声明以及其他以“可能导致”、“预计将”、“将继续”、“预计”、“估计”、“相信”、“打算”、“计划”、“预测”、“前景”或类似含义的词语标识的声明,但这些词语的缺失并不意味着该声明不是前瞻性声明。任何此类前瞻性声明均基于公司管理层当前的信念和预期,且固有地面临着重大业务、经济和竞争不确定性及意外情况,其中许多是难以预测的,通常超出公司控制范围。许多因素可能导致实际未来事件与本新闻稿中的前瞻性声明存在重大差异,包括但不限于该计划未被纽约证券交易所(NYSE American)接受的可能性,公司将无法满足A类普通股在纽约证券交易所(NYSE American)保持上市的其他持续上市要求;在FOXO所经营的竞争激烈且高度监管行业中的变化风险;不同竞争对手间的运营表现差异或影响FOXO业务的法律法规变化;实施FOXO的业务计划、预测和其他期望的能力;获得融资的能力;FOXO 有过亏损历史并可能无法在未来实现或维持盈利的风险;FOXO 在推进其目标或实现商业化和发展计划时可能无法建立或维护所需的关系;FOXO的知识产权的可执行性,包括其专利和对他人知识产权的潜在侵害;以及在 FOXO 所经营的生物技术行业或相关市场或行业中,经济下滑和监管环境变化的风险。上述因素列表并不详尽。读者应仔细考虑上述因素及在 FOXO 最近的10-K和10-Q表格报告中讨论的其他风险和不确定性,特别是这些报告的“风险因素”部分,以及FOXO提交或将提交给证券交易委员会(SEC)的其他文件。这些文件识别和处理可能导致实际事件和结果与前瞻性声明中所包含内容存在重大差异的其他重要风险和不确定性。前瞻性声明仅在作出声明的日期有效。读者应警惕不要对前瞻性声明给予过度信任,FOXO 不承担任何义务,也不打算更新或修订这些前瞻性声明,无论是由于新信息、未来事件,还是其他原因。
Contact:
Crescendo Communications, LLC
(212) 671-1020
foxo@crescendo-ir.com
联系:
Crescendo Communications, LLC
(212) 671-1020
foxo@crescendo-ir.com